CClinicalTrials.gg
RecruitingNCT06386835Updated Apr 26, 2024

Collagen Paste vs Mucosal Advancement Flap for FIA

An interventional study of Collagen Paste and Mucosal advancement in Fistula-in-ano, sponsored by Chinese University of Hong Kong. Recruiting at 2 sites in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-26.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The treatment for fistula-in-ano (FIA) remains a challenge to General and Colorectal Surgeons Worldwide. A variety of surgical treatments have been described for high anal fistulas, but none offers the panacea of fistula eradication with guaranteed preservation of continence. This study compares Collagen paste injection to mucosal advancement flap for the treatment of fistula-in-ano.

Read the detailed description

Rectal advancement flaps have been advocated as a means of closing high fistulas with preservation of the external sphincter muscle. With this technique, it shows promising results with success rate of approximately 60%. However, complications have been reported, in particular with a change of continence in 30-35% of patients.

Collagen paste is a novel sphincter-preserving method for fistula closure. Permacol (Medtronic, USA) is a sterile acellular cross-linked porcine dermal collagen matrix suspension. The paste-like suspension form a matrix that accelerates neovascularization, cellular infiltration which promotes healing and fistula closure. The theoretical benefits of paste form compared to previous collagen plug design is that the collagen can moulded into the fistula cavity or tract. This allows better tissue contact with the collagen thus improves healing and reduces the chance of dislodgement. Limited data is available to date. Success rates of collagen paste range from 47.6% to 63%. Hence it has a potential to be the first-line treatment for high FIA with low complication rates and without causing disruption to the anal sphincter complex.

02

Conditions studied

  • Fistula-in-ano

Browse trials for

03

In context

Fistula

731 studies on the registry are indexed under Fistula; 103 are open to participants now.

This study's planned enrollment of 118 is above the median of 60 across 484 interventional studies indexed under Fistula.

Browse Fistula studies →

Lead sponsor

Chinese University of Hong Kong is the lead sponsor of 1,419 studies on the registry; 487 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Clinical diagnosis of high cryptoglandular fistula-in-ano.
  • Patients must have undergone a prior EUA to characterise the nature of the fistula.
  • The fistula tract should be ≥ 2 cm in length.
  • Only a single internal fistula opening should be present at EUA, such that the fistula is suitable for treatment by insertion of a seton drain.
  • Patients must have been treated with a draining seton for a minimum period of 6 weeks prior to randomisation.
  • Patients must be aged ≥ 18 years and able to provide informed consent.
  • Fistulas must be of cryptoglandular aetiology.

Exclusion criteria

Exclusion Criteria:

  • Unable/unwilling to provide informed consent.
  • Contraindication to general anaesthesia or spinal anaesthesia.
  • Low trans-sphincteric fistulas.
  • Non-cryptoglandular fistulas (e.g. Crohn's disease, obstetric, irradiation, malignant, etc.).
  • Other perineal fistulas (e.g. rectovaginal fistulas, pouch-vaginal fistulas, etc.).
  • Complex disease in which more than one internal fistula opening is present and requiring concurrent insertion of more than one fistula plug.
  • Clinical evidence of active perianal sepsis. In the event that there is disagreement between clinical and radiological assessment of active sepsis/collection, the clinical opinion will prevail.
  • Cultural or religious objection to the use of pig tissue.
  • Absolute contraindication to magnetic resonance imaging (MRI) (e.g. cardiac pacemaker).
  • Patients with recurrent anal fistulas previously treated with a fistula plug.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
118 participants (estimated)

Study arms

  • Experimental
    Collagen Paste

    Seton is removed, the fistula tract is de-epithelialised and collagen paste applied.

    Procedure: Collagen Paste

  • Active comparator
    Mucosal Advancement Flap

    The internal opening is excised and is covered with a "U-shape" rectal mucosal flap

    Procedure: Mucosal advancement

Interventions

  • ProcedureCollagen Paste

    Collagen paste injection

  • ProcedureMucosal advancement

    Mucosal advancement flap

06

What researchers measure

Primary outcomes

  1. Clinical healing of Fistula-in-ano

    Clinical healing of the fistula-in-ano

    Time frame: 1 year

Secondary outcomes

  1. 30-day morbidity

    30-day morbidity using Clavien-Dindo classification

    Time frame: 30 days

  2. Quality of life score

    Assess effect on Quality of life post operatively using Short Form 36 Health Survey

    Time frame: 1 year

  3. Postoperative pain score

    assessment of postoperative pain using visual analog score from 0 (no pain) to 10 (severe pain)

    Time frame: 1 week

  4. Faecal incontinence rate

    Assess postoperative effect on continence

    Time frame: 1 year

  5. Hospital readmission rate

    Assess hospital re-admission rate

    Time frame: 1 year

07

Study locations

2 of 2 sites recruiting
  • Department of Surgery, Chinese University of Hong Kong
    Shatin, New Territories, Hong Kong
    Recruiting
  • Prince of Wlaes Hospital
    Sha Tin, Hong Kong
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06386835
Lead sponsor
Chinese University of Hong Kong
Responsible party
Kaori Futaba (Associate Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Apr 26, 2024
Start date
Jan 26, 2024
Primary completion
Mar 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Apr 26, 2024

Study contacts

Kaori Futaba, FRCS
Contact
kfutaba@surgery.cuhk.edu.hk
35051495

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion